Neuroblastoma Current State and Recent Updates

Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, with about 700 new cases of neuroblastoma seen each year in the United States. The 5-year survival rate for children with high-risk NBL is only 50-60%, and this survival rate has not improved over the last 10 years. High-r...

Full description

Saved in:
Bibliographic Details
Other Authors: Gowda, Chandrika (Editor)
Format: Electronic Book Chapter
Language:English
Published: IntechOpen 2017
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_129688
005 20231201
003 oapen
006 m o d
007 cr|mn|---annan
008 20231201s2017 xx |||||o ||| 0|eng d
020 |a 66615 
020 |a 9789535135845 
020 |a 9789535135838 
020 |a 9789535146193 
040 |a oapen  |c oapen 
024 7 |a 10.5772/66615  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a MJCL  |2 bicssc 
100 1 |a Gowda, Chandrika  |4 edt 
700 1 |a Gowda, Chandrika  |4 oth 
245 1 0 |a Neuroblastoma  |b Current State and Recent Updates 
260 |b IntechOpen  |c 2017 
300 |a 1 electronic resource (168 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, with about 700 new cases of neuroblastoma seen each year in the United States. The 5-year survival rate for children with high-risk NBL is only 50-60%, and this survival rate has not improved over the last 10 years. High-risk patients receive multimodality treatment, including chemotherapy, surgery, radiation therapy, biologic therapy and immunotherapy, all of which are associated with significant morbidity. Recent years have seen many advances in treatment of neuroblastoma, including therapeutic MIBG, immunotherapy, and personalized targeted therapy based on the genetic alterations seen in the tumor. The primary objective of this book is to provide the readers with a comprehensive review of neuroblastoma, from clinical aspects and the currently available treatment to recent advancements and future directions in the field of NBL treatment. The topics and chapters have been compiled keeping in mind a diverse group of readers in different areas of specialty such as pediatric oncology, surgery, radiation oncology, and immunology, as well as physician scientists and basic researchers working in the field of neuroblastoma. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/3.0/  |2 cc  |4 https://creativecommons.org/licenses/by/3.0/ 
546 |a English 
650 7 |a Oncology  |2 bicssc 
653 |a inflammation, epidemiology, immunotherapy, epigenetics, genetics, targeted therapy 
856 4 0 |a www.oapen.org  |u https://mts.intechopen.com/storage/books/6006/authors_book/authors_book.pdf  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/129688  |7 0  |z DOAB: description of the publication